Hugel hit Record High Quarterly Revenue and Operating Profit

Revenue of KRW95.4bn , operating profit of KRW42.4bn , net income of KRW37bn.

.. 17%, 51.

6%, and 72.7,%, respectively, year-on-year growth With solid performance in global markets such as Asia-Pacific and Europe , botulinum toxin and HA filler sales grew by 17.6% and 20%, respectively Focus on international expansion in the second half of the year.

.. Penetrate into the North American market with the first toxin shipment to the U.

S. SEOUL, South Korea , Aug. 7, 2024 /PRNewswire/ -- Hugel, a global total medical aesthetics company, announced consolidated financial statements for the second quarter of 2024 on August 7 th , reporting revenue of KRW95.

4billion , operating profit of KRW42.4billion , and net income of KRW37billion . Thanks to solid performance in global markets, revenue, operating profit, and net income increased 17%, 51.

6%, and 72.7%, respectively, compared to the same period last year. Notably, revenue and operating profit surpassed KRW90billion and KRW40billion for the first time, achieving all-time high quarterly results.

By product, sales of the botulinum toxin "Botulax (Export name: Letybo)" increased by 17.6% YoY. Hugel maintains its leading position in domestic market, while in global markets, sales grew in Europe and key Asia-Pacific regions including China , Thailand , Japan , Taiwan , and Australia .

International sales increased by 62% year-on-year with the largest quarterly shipment to China . Sales of HA fillers ("THE CHAEUM (Export name: Revolax, Derma.